104 related articles for article (PubMed ID: 22899289)
1. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
2. SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study.
Laga AC; Zhan Q; Weishaupt C; Ma J; Frank MH; Murphy GF
Exp Dermatol; 2011 Apr; 20(4):339-45. PubMed ID: 21410764
[TBL] [Abstract][Full Text] [Related]
3. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
4. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Screaton G; Hersey P
Hum Pathol; 2006 Oct; 37(10):1286-94. PubMed ID: 16949935
[TBL] [Abstract][Full Text] [Related]
5. The utility of SOX10 in mixed type desmoplastic melanoma with lymph node metastasis of the spindle cell component: A cautionary tale of inattentional blindness.
Shah A; Campbell K; Osmond A
J Cutan Pathol; 2024 Feb; 51(2):99-104. PubMed ID: 37818864
[TBL] [Abstract][Full Text] [Related]
6. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
8. Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
Meyer SN; Simmons E; Studer AC; Rauen KA; Kiuru M
Melanoma Res; 2023 Dec; 33(6):437-446. PubMed ID: 37578532
[TBL] [Abstract][Full Text] [Related]
9. Influence of Anatomic Locations of T1b Melanomas and Patient Age on Outcomes.
Huang MY; Chen A; Quarshie C; Masson R; Barajas G; Kim G; DeClerck B; Swanson MS; In GK; Kokot N; Pickering TA; Hu JC
J Drugs Dermatol; 2024 May; 23(5):306-310. PubMed ID: 38709694
[TBL] [Abstract][Full Text] [Related]
10. High nevus counts confer a favorable prognosis in melanoma patients.
Ribero S; Davies JR; Requena C; Carrera C; Glass D; Rull R; Vidal-Sicart S; Vilalta A; Alos L; Soriano V; Quaglino P; Traves V; Newton-Bishop JA; Nagore E; Malvehy J; Puig S; Bataille V
Int J Cancer; 2015 Oct; 137(7):1691-8. PubMed ID: 25809795
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils in metastatic melanoma.
Proffer SL; Guo R; Demer AM; Peters MS
Hum Pathol; 2023 Nov; 141():110-117. PubMed ID: 37574050
[TBL] [Abstract][Full Text] [Related]
12. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
Cohen PR; Bedikian AY; Kim KB
J Clin Aesthet Dermatol; 2013 May; 6(5):27-37. PubMed ID: 23710269
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
[TBL] [Abstract][Full Text] [Related]
14. PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma.
Hornick JL; Plaza JA; Mentzel T; Gru AA; Brenn T
Am J Surg Pathol; 2023 Dec; 47(12):1390-1397. PubMed ID: 37727938
[TBL] [Abstract][Full Text] [Related]
15. Analyzing the Spatial Randomness in the Distribution of Acquired Melanocytic Neoplasms.
Chousakos E; Kose K; Kurtansky NR; Dusza SW; Halpern AC; Marghoob AA
J Invest Dermatol; 2022 Dec; 142(12):3274-3281. PubMed ID: 35841946
[TBL] [Abstract][Full Text] [Related]
16. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Palmer AA; Zhang XD; Thompson JF; Bron LP; Hersey P
J Clin Pathol; 2005 Nov; 58(11):1163-9. PubMed ID: 16254105
[TBL] [Abstract][Full Text] [Related]
17. Perineural differentiation in neurotized nevi.
Leblebici C; Mod BN; Cin M; Özcan B
Pathol Res Pract; 2024 Mar; 255():155184. PubMed ID: 38324967
[TBL] [Abstract][Full Text] [Related]
18. Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma.
Moore DA; Saldanha G; Ehdode A; Mughal MZ; Potter L; Dyall L; Pringle JH
J Mol Diagn; 2015 Sep; 17(5):616-22. PubMed ID: 26134170
[TBL] [Abstract][Full Text] [Related]
19. The Level of Agreement between Self-Assessments and Examiner Assessments of Melanocytic Nevus Counts: Findings from an Evaluation of 4548 Double Assessments.
Gefeller O; Kaiser I; Brockmann EM; Uter W; Pfahlberg AB
Curr Oncol; 2024 Apr; 31(4):2221-2232. PubMed ID: 38668067
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Broggi MAS; Maillat L; Clement CC; Bordry N; Corthésy P; Auger A; Matter M; Hamelin R; Potin L; Demurtas D; Romano E; Harari A; Speiser DE; Santambrogio L; Swartz MA
J Exp Med; 2019 May; 216(5):1091-1107. PubMed ID: 30975896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
